Merck & Co Inc

Merck & Co. is a global health care company that develops and sells medicines, vaccines, and biologic therapies. The firm is noted for its significant contributions to the portfolio's performance, indicating its importance within the fund's holdings. The company is part of a group of firms that occupy important positions in their respective markets and are characterized by strong capital structures and reasonable progress in growing their bases of paying customers.

The letter discusses the biologics market and mentions Merck's cancer drug Keytruda as an example of a blockbuster biologic. It highlights the growth of biologics in the drug industry and the importance of bioprocessing in the value chain, but does not provide a specific investment thesis or directional argument regarding Merck itself.

Merck & Co. Inc. was a top contributor to our relative performance, indicating its positive impact on our portfolio. However, the letter does not provide specific arguments or directional language regarding the company's future prospects or valuation.

Merck has a long history, starting as a pharmacy in 1668 and now controlled by its founding family in the 13th generation, which signals resilience. The company has expanded into life sciences and semiconductor materials, accounting for about 60% of sales, and we expect these divisions to grow ahead of GDP. The pharma business, while diversified, is likely to deliver low single-digit growth. Current challenges in the life sciences and semiconductor sectors have created a value opportunity, with shares trading at 14 times earnings, the lowest since 2011, compared to historical high teen multiples.

We bought shares of Merck & Co., Inc., a large-cap pharmaceutical company. Merck’s largest product in terms of revenue is Keytruda, a cancer therapy which generated over $31 billion of revenue in 2025, representing close to 50% of the company’s revenue. Keytruda loses patent protection in 2028 which will result in biosimilar competition. Merck has been preparing to manage the impact of the Keytruda patent cliff through aggressive business development and pipeline investment. We think management has done a good job particularly with acquisitions and can effectively navigate this challenge.

Merck & Co. is a global health care company that develops and sells medicines, vaccines, and biologic therapies. The firm has shown strong performance, with a share price increase of 14.3% and a dividend yield of 2.87%. The manager believes that Merck & Co. occupies an important position in its market and has made reasonable progress in growing its base of paying customers and distributable cash flows, which supports multi-year dividend growth. This indicates good value for the investment.

Merck & Co. Inc (MRK) was one of our strongest performers this quarter, and we continue to hold it as we view it as attractively valued relative to its peers. The company has demonstrated resilience in a challenging market environment, and we believe it is well-positioned to capitalize on future opportunities. Our confidence in Merck's performance is bolstered by its strong fundamentals and market position, which we expect to contribute positively to our portfolio.

Merck & Co. Inc. was mentioned as a top contributor to the portfolio's relative performance, indicating its positive impact on returns. However, there is no explicit directional argument made regarding its future performance or valuation.

MERCK & CO. INC. was a top contributor to relative performance, impacting returns positively by 0.58%.

Merck & Co has a high Corporate Resilience score and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery. The stock’s weakness in Q2 was driven by a combination of concerns about its drug pipeline, particularly the competition from generic versions of Keytruda, and weaker market sentiment around Health Care stocks.